Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16772369 | 0.87 | SELP (0.35) | SELPALDH1A1CYP2D6CYP2C9MAPK1 | |
| SCHEMBL16772390 | 0.86 | SELP (0.33) | SELPALDH1A1CYP2D6MAPK1BCHE | |
| SCHEMBL16772388 | 0.84 | SELP (0.39) | SELPCYP2C9 | |
| SCHEMBL16772382 | 0.84 | SELP (0.39) | SELPCYP2C9 | |
| SCHEMBL16772374 | 0.81 | SELP (0.32) | SELP | |
| SCHEMBL27054999 | 0.79 | SELP (0.37) | SELPALDH1A1CYP2D6CYP2C9MAPK1 | |
| SCHEMBL15199322 | 0.77 | SELP (0.35) | SELPBCHE | |
| SCHEMBL27055012 | 0.77 | SELP (0.42) | SELPCYP2C9BCHE | |
| SCHEMBL27054862 | 0.76 | SELP (0.37) | SELPBCHE | |
| SCHEMBL30829360 | 0.76 | SELP (0.41) | SELPALDH1A1CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493497-B2 | Carbamate glycolipid and use thereof | RIKEN (JP) | 2016-11-15 | — | — | US | disclosed |
| US-20150152128-A1 | NEW CARBAMATE GLYCOLIPID AND USE THEREOF | RIKEN (JP) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152128-A1 | NEW CARBAMATE GLYCOLIPID AND USE THEREOF | SGMS1, CD14, SGMS2 | SELP 2028/4885ALDH1A1 3608/4885CYP2D6 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.